Thomas G. Martin, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Thomas G. Martin, MD

Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, and Associate Director, Myeloma Program, UCSF

Phone: (415) 353-2421 (appts)
Box 0324, UCSF
San Francisco, CA 94143-0324

View on UCSF Profiles

Cancer Center Membership

Program Member » Hematopoietic Malignancies

Education

Cornell University, B.A., 1985, Genetics
University of Connecticut School of Medicine, M.D., 1989, Medicine
Harbor-UCLA Medical Center, 1992, Internal Medicine
University of California, San Francisco, 1996, Hematology and Oncology


Professional Experience

  • 1993-1998
    Assistant Adjunct Professor, Hematology and Bone Marrow Transplant, Division of Hematology/Oncology, University of California, San Francisco, CA.
  • 1999-2001
    Assistant Professor of Medicine, Chief, Inpatient BMT Unit, Director, BMT Fellowship Program, Division of Blood and Marrow Transplantation, Department of Medicine, MD Anderson Cancer Center, Houston, TX
  • 2001-2003
    Director, Matched Unrelated Donor Program, Adult Leukemia and Bone Marrow Transplantation, University of California, CA
  • 2001-2003
    Assistant Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA
  • 2003-2008
    Associate Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA
  • 2004-Present
    Associate Director, Myeloma Clinic, Adult Ambulatory Care Clinic, University of California, San Francisco, CA.
  • 2006-Present
    Member, Committee on Human Research (CHR), University of California, San Francisco, CA.
  • 2006-Present
    Clinical Director, 11 Long Adult Stem Cell Transplantation
  • 2009-Present
    Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, University of California, San Francisco, CA

Honors & Awards

  • 1984
    Cornell Tradition Fellow Award
  • 1989
    LANGE Book Award for Scholarship in Internal Medicine, University of Connecticut, Farmington, CT
  • 2003
    Faculty Teaching Award, Division of Hematology/Oncology, University of California, San Francisco, CA

Selected Publications

  1. Bokori-Brown M, Martin TG, Naylor CE, Basak AK, Titball RW, Savva CG. Cryo-EM structure of lysenin pore elucidates membrane insertion by an aerolysin family protein. Nat Commun. 2016; 7:11293.
    View on PubMed
  2. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase II study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 Mar 1.
    View on PubMed
  3. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KM, Sayre PH, Wolf JL, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb 16.
    View on PubMed
  4. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-Term Outcomes of Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with Autologous Hematopoietic Cell Transplant in First Complete Remission. Leuk Lymphoma. 2015 Oct 22; 1-20.
    View on PubMed
  5. Seifert SA, Kirschner RI, Martin TG, Schrader RM, Karowski K, Anaradian PC. Acetaminophen concentrations prior to 4 hours of ingestion: Impact on diagnostic decision-making and treatment. Clin Toxicol (Phila). 2015 Aug; 53(7):618-23.
    View on PubMed
  6. Martin TG, Pata RW, D'Addario J, Yuknis L, Kingston R, Feinn R. Impact of age on haematological markers pre- and post-marathon running. J Sports Sci. 2015 Nov; 33(19):1988-97.
    View on PubMed
  7. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with Etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
    View on PubMed
  8. Stahl E, Martin TG, Praetorius F, Dietz H. Facile and scalable preparation of pure and dense DNA origami solutions. Angew Chem Int Ed Engl. 2014 Nov 17; 53(47):12735-40.
    View on PubMed
  9. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91.
    View on PubMed
  10. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4.
    View on PubMed
  11. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  12. Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology (Williston Park). 2013 Dec; 27 Suppl 3:4-10.
    View on PubMed
  13. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56.
    View on PubMed
  14. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
    View on PubMed
  15. Martin TG, Clarke DR, Bowrey DJ. Medical students in theatre: setting the scene. Med Teach. 2012; 34(4):337.
    View on PubMed
  16. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R. Autologous hematopoietic cell transplantation for high-risk ALL. Bone Marrow Transplant. 2011 Mar; 46(3):460-1.
    View on PubMed
  17. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Nov; 42(10):649-57.
    View on PubMed
  18. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64.
    View on PubMed
  19. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6.
    View on PubMed
  20. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant. 2006 Mar; 12(3):316-24.
    View on PubMed

Go to UCSF Profiles, powered by CTSI